Catalog # HM2327
SUMO-1, Human, mAb 1B12-E2
Please choose the quantity of items you wish to add to your cart…
Find distributor Post-translational modification regulated by conjugation of a small ubiquitin-like modifier (SUMO) is involved in various cellular processes such as transcriptional regulation, apoptosis and nuclear transport. Recent proteomic analyses in mammalian cells revealed that a number of SUMO substrates and specific modifications by SUMO-1 are involved in essential processes, including chromatin organization, transcription, RNA metabolism, immunomodulation and development of the innate immune system.
Application
Immuno assays, Paraffin sections, Western blot
Application Notes
Higher expression of SUMO-1 was detected in normal adrenal gland, esophagus, pancreas, liver, stomach, kidney, and uterus. the function of SUMO-1 may vary depending on the tissue types.
IHC-P: Tissue sections were deparaffinized in xylene, rehydrated, and treated with fresh 0.3% hydrogen peroxide in methanol for 15 min.
W: A non-reduced sample treatment was used.
Use
For Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:10.
Product type
Monoclonal antibodies
Amount
100 µg, 20 µg
Formulation
0.2 ml (100 µg/ml) 0.2 µm filtered antibody solution in PBS, containing 0.1% bovine serum albumin and 0.02% sodium azide.
Immunogen
hSUMO-1 and Lipoplex (O) complex
Isotype
Mouse IgG3
Species
Human
Alias
SMT3, GMP1, UBL1 and PIC1
Storage and stability
Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
Precautions
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Disease
Cardiology and metabolism
Protocol
CoA-TDS HM2300-HM2400
Safety Data Sheet
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA